Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...
المؤلفون الرئيسيون: | Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
American Society of Nephrology
2022
|
مواد مشابهة
-
Fibroblast growth factor-23 and risks of cardiovascular and non-cardiovascular diseases: a meta-analysis
حسب: Marthi, A, وآخرون
منشور في: (2018) -
Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
حسب: Lamprea-Montealegre, J, وآخرون
منشور في: (2019) -
Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
حسب: Ying Liang, وآخرون
منشور في: (2021-07-01) -
Corrigendum: Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
حسب: Ying Liang, وآخرون
منشور في: (2021-11-01) -
Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients—Cardiologists Be Aware
حسب: Anna Kurpas, وآخرون
منشور في: (2022-05-01)